As of now, Chris Smith holds a significant position within NeoGenomics, indicated by a hefty equity award package worth about $11.85 million, awarded when he joined the company. This equity package includes both restricted stock and stock options, structured to...
As of now, Chris Smith holds a significant position within NeoGenomics, indicated by a hefty equity award package worth about $11.85 million, awarded when he joined the company. This equity package includes both restricted stock and stock options, structured to vest over several years. His holdings reflect a considerable stake in NeoGenomics, aligning his interests with those of the shareholders. He hasn't completed stock sales recently, which suggests a commitment to the company's long-term growth. This approach can be viewed positively, as it indicates his confidence in the company's future. His wealth tied to the company has fluctuated since his start, emphasizing the importance of stock performance in his overall earnings.